文献速递胃肠动力与功能性疾病

人源CAZyme基因功能变异与IBS患者碳水化合物限制饮食疗效的关系

Functional Variation in Human CAZyme Genes in Relation to the Efficacy of a Carbohydrate-Restricted Diet in IBS Patients.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-10-14

DOMINO试验中,对饮食干预组196例和药物组54例IBS患者行6个hCAZyme基因靶向测序。饮食组中hCAZyme假性变异基因数与应答率正相关(P=0.03,OR=1.51,CI 0.99-2.32),IBS-D亚组携带者应答可能性为非携带者6倍(P=0.002,OR=6.33,CI 1.83-24.77),药物组未见此趋势。结论认为hCAZyme遗传变异可能与低碳水饮食疗效相关,需进一步验证。

要点

  • 药物组未观察到上述关联。

核心结论

  • hCAZyme遗传变异可能与碳水化合物限制饮食的疗效相关。
  • 该发现需进一步验证和重复,包括机制研究。

研究设计与样本

  • DOMINO试验中饮食组196例和药物组54例IBS患者,对6个hCAZyme基因行靶向测序。
  • 采用年龄和性别校正的logistic回归,按携带/非携带分组及受累基因数进行累积和定量分析。

主要发现

  • 药物组未观察到上述趋势。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需额外测试和重复发现,包括机制研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Limiting the dietary intake of certain carbohydrates has therapeutic effects in some but not all irritable bowel syndrome (IBS) patients. We investigated genetic variation in human Carbohydrate-Active enZYmes (hCAZymes) genes in relationship to the response to a FODMAP-lowering diet in the DOMINO study. METHODS: hCAZy polymorphism was studied in patients with IBS from the dietary (FODMAP-lowering; n = 196) and medication (otilonium bromide; n = 54) arms of the DOMINO trial via targeted sequencing of 6 genes of interest (AMY2B, LCT, MGAM, MGAM2, SI, and TREH). hCAZyme defective (hypomorphic) variants were identified via computational annotation using clinical pathogenicity classifiers. Age- and sex-adjusted logistic regression was used to test hCAZyme polymorphisms in cumulative analyses where IBS patients were stratified into carrier and non-carrier groups (collapsing all hCAZyme hypomorphic variants into a single bin). Quantitative analysis of hCAZyme variation was also performed, in which the number of hCAZyme genes affected by a hypomorphic variant was taken into account. RESULTS: In the dietary arm, the number of hypomorphic hCAZyme genes positively correlated with treatment response rate (P = .03; odds ratio = 1.51; confidence interval = 0.99-2.32). In the IBS-D group (n = 55), hCAZyme carriers were 6 times more likely to respond to the diet than non-carriers (P = .002; odds ratio = 6.33; confidence interval = 1.83-24.77). These trends were not observed in the medication arm. CONCLUSIONS: hCAZYme genetic variation may be relevant to the efficacy of a carbohydrate-lowering diet. This warrants additional testing and replication of findings, including mechanistic investigations of this phenomenon.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Zamfir-Taranu A, Löscher BS, Carbone F, et al. Functional Variation in Human CAZyme Genes in Relation to the Efficacy of a Carbohydrate-Restricted Diet in IBS Patients. Clin Gastroenterol Hepatol. 2024. PMID: 39413891. doi:10.1016/j.cgh.2024.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。